A 52-week placebo-controlled randomized Phase 3 study to evaluate the safety and efficacy of seladelpar in subjects with primary biliary cholangitis (PBC) and an inadequate response to or an intolerance to ursodeoxycholic acid (UDCA)

Research Summary

Research Overview
Project Status Open
Proposed End Date 21/11/2020
Study Run through CRF? No
Target number of patients agreed to recruit 2
Recruitment so far 0